Managing ADHD in children, adolescents, and adults with comorbid anxiety

Journal of Clinical Psychiatry

Volumn 68, Issue 3, 2007, Pages 451-462

  Adler, Lenard A ^a   Barkley, Russell A ^b   Newcorn, Jeffrey H ^c   Spencer, Thomas J ^d   Weiss, Margaret D ^e  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b State University of New York Upstate Medical University: College of Medicine   (United States)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHETAMINE; ATOMOXETINE; BENZODIAZEPINE DERIVATIVE; BUSPIRONE; CYTOCHROME P450 2D6; DEXAMPHETAMINE; FLUOXETINE; FLUVOXAMINE; METHYLPHENIDATE; PAROXETINE; PLACEBO; SEROTONIN UPTAKE INHIBITOR;

AGE DISTRIBUTION; AGORAPHOBIA; ANXIETY DISORDER; ATTENTION DEFICIT DISORDER; BEHAVIOR THERAPY; BLOOD PRESSURE; CHILD SEXUAL ABUSE; CLINICAL FEATURE; CLINICAL PRACTICE; CLINICAL TRIAL; COGNITIVE THERAPY; COMBINATION CHEMOTHERAPY; COMORBIDITY; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DISEASE COURSE; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFECT; FAMILY STRESS; GENERALIZED ANXIETY DISORDER; HAMILTON ANXIETY SCALE; HUMAN; LOW DRUG DOSE; MEDICAL RESEARCH; MONOTHERAPY; PANIC; PHOBIA; POSTTRAUMATIC STRESS DISORDER; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; PSYCHOSOCIAL CARE; PSYCHOTHERAPY; PULSE RATE; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SEPARATION ANXIETY; SEX DIFFERENCE; SIDE EFFECT; SOCIAL PHOBIA; SUICIDE ATTEMPT; SYMPTOMATOLOGY; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

EID: 33947714310     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/jcp.v68n0316     Document Type: Conference Paper

References (63)

1. Goldman LS, Genel M, Bezman RJ, et al. Diagnosis and treatment of attention-deficit/hyperactivity disorder in children and adolescents. JAMA 1998;279:1100-1107
2. Wender PH, Wolf LE, Wasserstein J. Adults with ADHD: an overview. Ann N Y Acad Sci 2001;931:1-16
3. Leibson CL, Katusic SK, Babaresi WJ, et al. Use and costs of medical care for children and adolescents with and without attention-deficit/hyperactivity disorder. JAMA 2001;285:60-66
4. Swensen AR, Birnbaum HG, Secnik K, et al. Attention-deficit/hyperactivity disorder: increased costs for patients and their families. J Am Acad Child Adolesc Psychiatry 2003;42: 1415-1423
5. Barkley RA. Attention-Deficit Hyperactivity Disorder: A Handbook for Diagnosis and Treatment. 3rd ed. New York, NY: Guilford Press; 2006
6. National Center for Educational Statistics. Dropout Rates in the United States: 2000. Washington, DC: US Department of Education; 2001. NCES pub No. 2002-114. Available at: http://nces.ed.gov/pubs2002/2002114.pdf. Accessed December 5, 2006
7. Barkley RA. Major life activity and health outcomes associated with attention-deficit/hyperactivity disorder. J Clin Psychiatry 2002; 63(suppl 12):10-15
8. Barkley RA, Murphy KR, Kwasnik D. Motor vehicle driving competencies and risks in teens and young adults with attention deficit hyperactivity disorder. Pediatrics 1996;98(6, pt 1): 1089-1095
9. McGough JJ, Smalley SL, McCracken JT, et al. Psychiatric comorbidity in adult attention deficit hyperactivity disorder: findings from multiplex families. Am J Psychiatry 2005;162:1621-1627
10. The MTA Cooperative Group. A 14-month randomized clinical trial of treatment strategies for attention deficit hyperactivity disorder. Arch Gen Psychiatry 1999;56:1073-1086
11. Pliszka SR. Effect of anxiety on cognition, behavior, and stimulant response in ADHD. J Am Acad Child Adolesc Psychiatry 1989;28: 882-887
12. American Academy of Pediatrics. Clinical practice guideline: treatment of the school-aged child with attention-deficit/hyperactivity disorder. Pediatrics 2001;108:1033-1044
13. Greenhill LL, Pliszka S, Dulcan MK, et al, for the American Academy of Child and Adolescent Psychiatry. Practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults. J Am Acad Child Adolesc Psychiatry 2002;41(suppl 2): 26S-49S
14. Rappley MD, Gardiner JC, Jetton JR, et al. The use of methylphenidate in Michigan. Arch Pediatr Adolesc Med 1995;149:675-679
15. Wolraich ML, Lindgren S, Stromquist A, et al. Stimulant medication use by primary care physicians in the treatment of attention deficit hyperactivity disorder. Pediatrics 1990;86:95-101
16. Biederman J, Newcorn J, Sprich S. Comorbidity of attention deficit hyperactivity disorder with conduct, depressive, anxiety, and other disorders. Am J Psychiatry 1991;148:564-577
17. Culpepper L. Primary care treatment of attention-deficit/hyperactivity disorder. J Clin Psychiatry 2006;67(suppl 8):51-58
18. Biederman J, Faraone SV, Marrs A, et al. Panic disorder and agoraphobia in consecutively referred children and adolescents. J Am Acad Child Adolesc Psychiatry 1997;36:214-223
19. Biederman J, Faraone SV. The Massachusetts General Hospital studies of gender influences on attention-deficit/hyperactivity disorder in youth and relatives. Psychiatr Clin North Am 2004;27: 225-232
20. Biederman J, Mick E, Faraone SV, et al. Influence of gender on attention deficit hyperactivity disorder in children referred to a psychiatric clinic. Am J Psychiatry 2002;159:36-42
21. Angold A, Costello EJ, Erkanli A. Comorbidity. J Child Psychol Psychiatry 1999;40:57-87
22. Biederman J, Faraone SV, Milberger S, et al. A prospective 4-year follow-up study of attention-deficit hyperactivity and related disorders. Arch Gen Psychiatry 1996;53:437-446
23. Peterson BS, Pine DS, Cohen P, et al. Prospective, longitudinal study of tic, obsessive-compulsive, and attention-deficit/hyperactivity disorders in an epidemiological sample. J Am Acad Child Adolesc Psychiatry 2001;40:685-695
24. Hettema JM, Neale MC, Kendler KS. A review and meta-analysis of the genetic epidemiology of anxiety disorders. Am J Psychiatry 2001;158: 1568-1578
25. Biederman J, Faraone SV, Keenan K, et al. Further evidence for family-genetic risk factors in attention deficit hyperactivity disorder: patterns of comorbidity in probands and relatives psychiatrically and pediatrically referred samples. Arch Gen Psychiatry 1992;49:728-738
26. Weissman MM, Leckman JF, Merikangas KR, et al. Depression and anxiety disorders in parents and children: results from the Yale family study. Arch Gen Psychiatry 1984;41:845-852
27. Kessler RC, Adler L, Barkley R, et al. The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication. Am J Psychiatry 2006;163: 716-723
28. Biederman J, Faraone SV, Spencer T, et al. Patterns of psychiatric comorbidity, cognition, and psychosocial functioning in adults with attention deficit hyperactivity disorder. Am J Psychiatry 1993;150:1792-1798
29. Biederman J. Impact of comorbidity in adults with attention-deficit/ hyperactivity disorder. J Clin Psychiatry 2004;65(suppl 3):3-7
30. Barkley RA, Murphy KR, Fischer M. The Science of ADHD in Adults: Clinic-Referred Adults and Children Grown Up. New York, NY: Guilford; 2007
31. Pliszka SR. Comorbidity of attention-deficit/hyperactivity disorder with psychiatric disorder: an overview. J Clin Psychiatry 1998;59(suppl 7): 50-58
32. Kumpulainen K, Rasanen E, Henttonen I, et al. Bullying and psychiatric symptoms among elementary school-age children. Child Abuse Negl 1998;22:705-717
33. Endo T, Sugiyama T, Someya T. Attention-deficit/hyperactivity disorder and dissociative disorder among abused children. Psychiatry Clin Neurosci 2006;60:434-438
34. Rucklidge JJ, Brown DL, Crawford S, et al. Retrospective reports of childhood trauma in adults with ADHD. J Atten Disord 2006;9: 631-641
35. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision. Washington, DC: American Psychiatric Association; 2000
36. Spencer TJ. ADHD and comorbidity in childhood. J Clin Psychiatry 2006;67(Suppl 8):27-31
37. Weiss MD, Weiss JR. A guide to the treatment of adults with ADHD. J Clin Psychiatry 2004;65 (suppl 3):27-37
38. Pliszka SR. Patterns of psychiatric comorbidity with attention-deficit/ hyperactivity disorder. Child Adolesc Psychiatr Clin North Am 2000;9: 525-540
39. Pliszka SR, Greenhill LL, Crismon ML, et al. The Texas Children's Medication Algorithm Project: report of the Texas Consensus Conference Panel on Medication Treatment of Childhood Attention-Deficit/Hyperactivity Disorder, pt 2: tactics. J Am Acad Child Adolesc Psychiatry 2000;39:920-927
40. Pliszka SR. Texas Children's Medication Algorithm for ADHD: clarification [letter]. J Am Acad Child Adolesc Psychiatry 2001;40:991
41. Weiss M, Hechtman L, for the Adult ADHD Research Group. A randomized double-blind trial of paroxetine and/or dextroamphetamine and problem-focused therapy for attention-deficit/hyperactivity disorder in adults. J Clin Psychiatry 2006;67:611-619
42. Tannock R, Ickowicz A, Schachar R. Differential effects of methylphenidate on working memory in ADHD children with and without comorbid anxiety. J Am Acad Child Adolesc Psychiatry 1995;34:886-896
43. Taylor E, Schachar R, Thorley G, et al. Which boys respond to stimulant medication? a controlled trial of methylphenidate in boys with disruptive behavior. Psychol Med 1987;17: 121-143
44. DuPaul GJ, Barkley RA, McMurray MB. Response of children with ADHD to methylphenidate: interaction with internalizing symptoms. J Am Acad Child Adolesc Psychiatry 1994;33:894-903
45. The MTA Cooperative Group. Moderators and mediators of treatment response for children with attention-deficit/hyperactivity disorder: the Multimodal Treatment Study of Children with Attention-Deficit/Hyperactivity Disorder. Arch Gen Psychiatry 1999;56:1088-1096
46. Abikoff H, McGough J, Vitiello B, et al. Sequential pharmacotherapy for children with comorbid attention-deficit/hyperactivity and anxiety disorders. J Am Acad Child Adolesc Psychiatry 2005;44:418-427
47. Diamond IR, Tannock R, Schachar RJ. Response to methylphenidate in children with ADHD and comorbid anxiety. J Am Acad Child Adolesc Psychiatry 1999;38:402-409
48. Geller D, Donnelly C, Lopez F, et al. Atomoxetine treatment for pediatric patients with ADHD and comorbid anxiety [poster]. Presented at the 53rd annual meeting of the American Academy of Child and Adolescent Psychiatry: October 24-29, 2006; San Diego, Calif
49. Kratochvil CJ, Newcorn JH, Arnold LE, et al. Atomoxetine alone or combined with fluoxetine for treating ADHD with comorbid depressive or anxiety symptoms. J Am Acad Child Adolesc Psychiatry 2005;44:915-924
50. Riddle MA, Reeve EA, Yaryura-Tobias JA, et al. Fluvoxamine for children and adolescents with obsessive-compulsive disorder: a randomized, controlled, multicenter trial. J Am Acad Child Adolesc Psychiatry 2001;40:222-229
51. Seidel L, Walkup JT. Selective serotonin reuptake inhibitor use in the treatment of the pediatric non-obsessive-compulsive disorder anxiety disorders. J Child Adolesc Psychopharmacol 2006;16:171-179
52. Spencer T, Wilens T, Biederman J, et al. A double-blind, crossover comparison of methylphenidate and placebo in adults with childhood-onset attention-deficit hyperactivity disorder. Arch Gen Psychiatry 1995;52: 434-443
53. Spencer T, Biederman J, Wilens T, et al. Efficacy of a mixed amphetamine salts compound in adults with attention-deficit/hyperactivity disorder. Arch Gen Psychiatry 2001;58:775-782
54. Spencer T, Biederman J, Wilens T, et al. Effectiveness and tolerability of tomoxetine in adults with attention deficit hyperactivity disorder. Am J Psychiatry 1998;155:693-695
55. Spencer TJ, Biederman J, Wilens T, et al. A large, double-blind, randomized clinical trial of methylphenidate in the treatment of adults with attention-deficit/hyperactiviry disorder. Biol Psychiatry 2005;57:456-463
56. Spencer TJ, Faraone SV, Michelson D, et al. Atomoxetine and adult attention-deficit/hyperactivity disorder: the effects of comorbidity. J Clin Psychiatry 2006;67:415-420
57. Jensen PS, Hinshaw SP, Swanson JM, et al. Findings from the NIMH Multimodal Treatment Study of ADHD (MTA): implications and applications for primary care providers. J Dev Behav Pediatr 2001;22:60-73
58. March JS, Swanson JM, Arnold LE, et al. Anxiety as a predictor and outcome variable in the Multimodal Treatment Study of Children with ADHD (MTA). J Abnorm Child Psychol 2000; 28:527-541
59. Jensen PS, Hinshaw SP, Kraemer HC, et al. ADHD comorbidity findings from the MTA study: comparing comorbid subgroups. J Am Acad Child Adolesc Psychiatry 2001;40:147-158
60. Antshel KM, Reiner R. Social skills training in children with attention deficit hyperactivity disorder: a randomized-controlled clinical trial. J Clin Child Adolesc Psychol 2003;32: 153-165
61. van der Oord S, Prins PJ, Oosterlaan J, et al. Does brief, clinically based, intensive multimodal behavior therapy enhance the effects of methylphenidate in children with ADHD? Eur Child Adolesc Psychiatry 2006;[E-pub ahead of print]
62. Safren SA, Otto MW, Sprich S, et al. Cognitive-behavioral therapy for ADHD in medication-treated adults with continued symptoms. Behav Res Ther 2005;43:831-842
63. March J, Silva S, Petrycki S, et al, for the Treatment for Adolescents With Depression Study (TADS) Team. Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial. JAMA 2004;292:807-820